Free Trial

Bright Minds Biosciences Q1 2023 Earnings Report

Bright Minds Biosciences logo
$39.75 +0.93 (+2.40%)
(As of 12/17/2024 ET)

Bright Minds Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Trump’s Secret Manhattan Project (Ad)

On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.

Click here and I’ll show you exactly how to position your money

Bright Minds Biosciences Earnings Headlines

Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Bright Minds Biosciences to Present Novel Epilepsy Data
Bright Minds Biosciences participates in a conference call with Truist
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG), a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

View Bright Minds Biosciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings